关注肝病患者肌少症

doi:10.3969/j.issn.1672-5069.2017.05.002

摘要/Abstract

Key words: Liver disease, Sarcopenia, Muscle loss, Sarcopenic obesity, Malnutrition

吴江，范建高. 关注肝病患者肌少症[J]. 实用肝脏病杂志, 2017, 20(5): 516-519.

Wu Jiang， Fan Jiangao.. Sarcopenia:a new focus in liver disease[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2017, 20(5): 516-519.

[1] Rosenberg IH. Sarcopenia:origins and clinical relevance. J Nutr，1997，127（Suppl 5）:990S-991S.
[2] Sinclair M，Gow PJ，Grossmann M，et al. Review article: sarcopenia in cirrhosis-aetiology，implications and potential therapeutic interventions. Aliment Pharmacol Ther，2016，43（7）:765-777.
[3] Dasarathy S，Merli M. Sarcopenia from mechanism to diagnosis and treatment in liver disease. J Hepatol，2016，65（6）:1232-1244.
[4] Hara N，Iwasa M，Sugimoto R，et al. Sarcopenia and sarcopenic obesity are prognostic factors for overall survival in patients with cirrhosis. Intern Med，2016，55（8）:863-870.
[5] Durand F，Buyse S，Francoz C，et al. Prognostic value of muscle atrophy in cirrhosis using psoas muscle thickness on computed tomography. J Hepatol， 2014，60（6）:1151-1157.
[6] Merli M，Giusto M，Lucidi C，et al. Muscle depletion increases the risk of overt and minimal hepatic encephalopathy:results of a prospective study. Metab Brain Dis，2013，28（2）:281-284.
[7] van Vugt JL，Levolger S，de Bruin RW，et al. Systematic review and Meta-analysis of the impact of computed tomography-assessed skeletal muscle mass on outcome in patients awaiting or undergoing liver transplantation. Am J Transplant，2016，16（8）:2277-2292.
[8] Quigley EM，Stanton C，Murphy EF. The gut microbiota and the liver. Pathophysiological and clinical implications. J Hepatol，2013，58（5）:1020-1027.
[9] Dasarathy S. Consilience in sarcopenia of cirrhosis. J Cachexia Sarcopenia Muscle，2012，3（4）:225-237.
[10] Garcia PS，Cabbabe A，Kambadur R，et al. Brief-reports:elevated myostatin levels in patients with liver disease:a potential contributor to skeletal muscle wasting. Anesth Analg，2010，111（3）:707-709.
[11] Tsien C，Davuluri G，Singh D，et al. Metabolic and molecular responses to leucine-enriched branched chain amino acid supplementation in the skeletal muscle of alcoholic cirrhosis. Hepatology，2015，61（6）:2018-2029.
[12] Beyer I，Mets T，Bautmans I. Chronic low-grade inflammation and age-related sarcopenia. Curr Opin Clin Nutr Metab Care，2012，15（1）:12-22.
[13] Tovo CV，Fernandes SA，Buss C，et al. Sarcopenia and non-alcoholic fatty liver disease:Is there a relationship A systematic review. World J Hepatol，2017，9（6）:326-332.
[14] Lee YH，Jung KS，Kim SU，et al. Sarcopaenia is associated with NAFLD independently of obesity and insulin resistance:Nationwide surveys （KNHANES 2008-2011）. J Hepatol，2015，63（2）:486-493.
[15] Lee YH，Kim SU，Song K，et al. Sarcopenia is associated with significant liver fibrosis independently of obesity and insulin resistance in nonalcoholic fatty liver disease:Nationwide surveys （KNHANES 2008-2011）. Hepatology，2016，63（3）:776-786.
[16] Cruz-Jentoft AJ，Baeyens JP，Bauer JM，et al. Sarcopenia: European consensus on definition and diagnosis:Report of the European Working Group on Sarcopenia in Older People. Age Ageing，2010，39（4）:412-423.
[17] Fielding RA，Vellas B，Evans WJ，et al. Sarcopenia:an undiagnosed condition in older adults. Current consensus definition: prevalence，etiology，and consequences. International working group on sarcopenia. J Am Med Dir Assoc，2011，12（4）:249-256.
[18] Chen LK，Liu LK，Woo J，et al. Sarcopenia in Asia:consensus report of the Asian Working Group for Sarcopenia. J Am Med Dir Assoc，2014，15（2）:95-101.
[19] 余卫，程晓光，袁凌青. 肌少症的评估方法. 中华骨质疏松和骨矿盐疾病杂志，2016，9（3）:240-246.
[20] Prado CM，Lieffers JR，McCargar LJ，et al. Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts:a population-based study. Lancet Oncol，2008，9（7）:629-635.
[21] Lauretani F，Russo CR，Bandinelli S，et al. Age-associated changes
in skeletal muscles and their effect on mobility:an operational diagnosis of sarcopenia. J Appl Physiol（1985），2003，95（5）:1851-1860.
[22] Tsien C，Shah SN，McCullough AJ，et al. Reversal of sarcopenia predicts survival after a transjugular intrahepatic portosystemic stent. Eur J Gastroenterol Hepatol，2013，25（1）:85-93.
[23] 中国营养学会老年营养分会. 中国营养学会临床营养分会，中华医学会肠外肠内营养学分会老年营养支持学组. 肌肉衰减综合征营养与运动干预中国专家共识（节录）. 营养学报，2015，37（4）:320-324.
[24] Plauth M，Cabre E，Riggio O，et al. ESPEN Guidelines on Enteral Nutrition:Liver disease. Clin Nutr，2006，25（2）:285-294.
[25] Ney M，Vandermeer B，van Zanten SJ，et al. Meta-analysis:oral or enteral nutritional supplementation in cirrhosis. Aliment Pharmacol Ther，2013，37（7）:672-679.
[26] Tsien CD，McCullough AJ，Dasarathy S. Late evening snack: exploiting a period of anabolic opportunity in cirrhosis. J Gastroenterol Hepatol，2012，27（3）:430-441.
[27] Morihara D，Iwata K，Hanano T，et al. Late-evening snack with branched-chain amino acids improves liver function after radiofrequency ablation for hepatocellular carcinoma. Hepatol Res，2012，42（7）:658-667.
[28] Hickman IJ，Jonsson JR，Prins JB，et al. Modest weight loss and physical activity in overweight patients with chronic liver disease results in sustained improvements in alanine aminotransferase，fasting insulin，and quality of life. Gut，2004，53（3）:413-419.
[29] Roman E，Torrades MT，Nadal MJ，et al. Randomized pilot study:effects of an exercise programme and leucine supplementation in patients with cirrhosis. Dig Dis Sci，2014，59（8）:1966-1975.
[30] Hayashi F，Matsumoto Y，Momoki C，et al. Physical inactivity and insufficient dietary intake are associated with the frequency of sarcopenia in patients with compensated viral liver cirrhosis. Hepatol Res，2013，43（12）:1264-1275.
[31] 曹海霞，范建高. 肝硬化患者营养评估及营养支持治疗. 实用肝脏病杂志，2014，17（5）:459-462.
[32] 段钟平. 肝病营养问题再关注. 实用肝脏病杂志，2014，17（5）:449-451.

关注肝病患者肌少症

Sarcopenia:a new focus in liver disease

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	任俞霏, 陈小青, 孔维宗, 王迎春. 丹酚酸B对非酒精性脂肪性肝病细胞模型自噬功能的影响^*[J]. 实用肝脏病杂志, 2019, 22(6): 804-807.
[2]	李颖怡, 郭翠芬, 章瑞南, 汪保灿, 潘勤, 汪余勤, 曹海霞, 范建高. ALDH2 rs671基因多态性与非酒精性脂肪性肝病相关性研究^*[J]. 实用肝脏病杂志, 2019, 22(6): 848-851.
[3]	邢欣, 魏重操, 周咪咪, 李小玲, 邓江, 鲁晓岚. 牛磺熊去氧胆酸与熊去氧胆酸治疗非酒精性脂肪性肝病患者疗效和安全性的Meta分析[J]. 实用肝脏病杂志, 2019, 22(6): 852-855.
[4]	丁雯瑾, 范建高. 胆汁淤积性肝病相关并发症的处理^*[J]. 实用肝脏病杂志, 2019, 22(6): 938-940.
[5]	中华医学会肝病学分会, 中华医学会消化病学分会. 终末期肝病临床营养指南[J]. 实用肝脏病杂志, 2019, 22(5): 624-635.
[6]	张胥磊, 杨庆余, 韩秋玉, 缪鋆鋆, 蔡仁诚, 马亦旻. 自拟中药治疗非酒精性脂肪性肝病患者血清炎症反应指标水平的变化*[J]. 实用肝脏病杂志, 2019, 22(5): 660-663.
[7]	陆伦根. 胆汁淤积性肝病的正确认识与科学管理[J]. 实用肝脏病杂志, 2019, 22(5): 754-757.
[8]	洪佳, 吴晓宁, 尤红. 胆汁淤积性肝病的规范化诊断[J]. 实用肝脏病杂志, 2019, 22(5): 758-760.
[9]	唐承薇. 慢性肝病与血小板减少：临床处理观念的转变[J]. 实用肝脏病杂志, 2019, 22(4): 457-458.
[10]	延喜胜, 李伟, 王剑. 酒精性肝病患者血清细胞因子水平和肠道菌群分布变化研究^*[J]. 实用肝脏病杂志, 2019, 22(4): 518-521.
[11]	张兰华, 邵琴, 夏振娟. 非酒精性脂肪性肝病儿童血清25-（OH）D3和IL-17水平变化初步研究^*[J]. 实用肝脏病杂志, 2019, 22(4): 522-525.
[12]	谢晓, 刘婷, 董志霞, 夏幼辰, 张启迪, 曲颖, 蔡晓波, 徐铭益, 陆伦根. FibroTouch检测肝脏受控衰减参数对肝脂肪变的诊断价值分析^*[J]. 实用肝脏病杂志, 2019, 22(4): 526-529.
[13]	符亮, 吴冬冰, 纪新尊, 万鸿兴, 李文刚, 饶卉明, 钟静, 江婷婷. 超声定量评估非酒精性脂肪性肝病患者肝脏ARFI值对显著NASH的诊断价值分析[J]. 实用肝脏病杂志, 2019, 22(3): 377-380.
[14]	王海舫, 杨大伟, 贾蓓, 张岁, 柳立平, 马文波, 解从君, 刘明书. 营养支持联合美他多辛治疗酒精性肝病患者肝功能和外周血细胞参数的变化[J]. 实用肝脏病杂志, 2019, 22(3): 381-384.
[15]	朱光曦（综述）, 文良志, 陈东风（审校）. 非酒精性脂肪性肝病相关肝细胞癌发病机制研究进展[J]. 实用肝脏病杂志, 2019, 22(3): 453-456.